Immucura applies the Nobel Prize-winning Dendritic Cell Therapy. DCT is a non-invasive cancer therapy that works by boosting the immune system and empowering it to fight cancer. The therapy has no side effects, and it can be used primarily or in combination with other therapies. It can also be done at every stage and moment of cancer.
Apart from the simplicity of the process, Immucura highlights the safety of therapy, as there are no negative side effects. Since the foundation of the company, no medical incidents or adverse reactions connected to Dendritic Cell Therapy have been reported. Immucura’s main focus is to ensure the comfort and safety of our patients.
Dendritic Cell Therapy
One of Immucura’s patients states the following: “DCT is non-intrusive, super easy with no side effects or unpleasantness. It was excellent. They injected the vaccine into my skin, I walked out, and it just started getting better.”
The process of the therapy starts with the withdrawal of a small amount of blood from the patient, which is then taken to a lab to be processed. In the lab monocytes are extracted from the blood and cultivated into dendritic cells, these cells are then introduced to the cancer antigens, which primes them before they are re-injected into the body. At this point, the body’s immune system takes over, using the Dendritic Cells to activate cancer-killing cytotoxic T-cells, and finally, the healing process begins.
Immucura also offers a range of dedicated scientific studies about Dendritic Cell Therapy on the company’s website, as well as first-hand experience shared by patients:
“The whole team and everyone involved was fantastic. I felt like they went out of their way for me. I was contacted via Zoom video calls, which were great because I felt like they really cared about me. Most of all, I have to say that I was in good hands.” (Immucura’s patient Salvatore)
“Both my wife and I are super thankful for your good treatment and for what you have done for us.” (Immucura patient Rafael)
Statement from the founder
Founder Johannes Schumacher has been actively involved at Immucura since the very beginning. When asked about the success rates and safety of the applied therapies, he says:
“I’m glad that with hundreds of patients served until now, there was no medical incidence and all patients were tolerating the medical measures well.”
He continues to speak about Dendritic Cell Therapy, “As we have seen in these years, the memory effect of DCT might even provide a long-term positive result. The combination of cell immunotherapy and a bespoke natural remedies approach is the union of two best practices that already alone show significantly higher survival rates than general practice treatments.”
For more information on Dendritic Cell Therapy, visit our homepage: www.immucura.com
Immucura and a growing number of medical professionals feel that immunotherapy is the future of cancer treatment. If you have any questions regarding Dendritic Cell Therapy, email to: firstname.lastname@example.org
Immucura identifier : BGI22_397EN